The current secondary analysis revealed that postprandial plasma aGLP-1 and aGIP excursions modified by 24-week add-on treatment with an αGI miglitol and/or a DPP-4 inhibitor sitagliptin did not affect skeletal muscle mass regulation in T2D patients without sarcopenia. Here, DPP4 is linked to type 2 diabetes mellitus.